Is This the Right Time to Retain Omnicell Stock in Your Portfolio?

OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.

Zacks Investment Research • Oct 13, 2026

Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Release Third Quarter 2026 Financial Results on October 29, 2026.

Business Wire • Oct 8, 2026

Omnicell (OMCL) is a Top-Ranked Value Stock: Should You Buy?

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Oct 2, 2026

Here's Why Omnicell (OMCL) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Sep 16, 2026

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

Integration brings serialized product verification and traceability directly into medication receiving workflows, intended to enable more efficient pharmacy operations without separate compliance processes. BOSTON, Sept.

PRNewsWire • Sep 3, 2026

Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference.

Business Wire • Aug 31, 2026

Why Omnicell (OMCL) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Aug 24, 2026

Omnicell President Sells 6,753 Shares

The disposal comprised 6,753 shares representing a total transaction value of ~$250,000. The transaction reduced the insider's direct equity holdings by 4%.

The Motley Fool • Aug 20, 2026

Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins

OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.

Zacks Investment Research • Aug 13, 2026

OMCL Falls 20.1% in a Month as Booking and Margin Risks Build

Omnicell's 20.1% monthly slide reflects booking uncertainty, margin pressure and refresh-cycle risks despite a higher 2026 profit outlook.

Zacks Investment Research • Aug 12, 2026